medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Disease&severity&dictates&SARS0CoV020specific&neutralizing&antibody&responses&
in&COVID019&
&
Xiangyu( Chen1,12,( Zhiwei( Pan1,12,( Shuai( Yue1,12,( Fei( Yu2,12,( Junsong( Zhang3,12,( Yang(
Yang1,(Ren(Li4,5,(Bingfeng(Liu2,(Xiaofan(Yang2,(Leiqiong(Gao1,(Zhirong(Li1,(Yao(Lin1,(
Qizhao( Huang6,( Lifan( Xu1,( Jianfang( Tang1,( Li( Hu1,( Jing( Zhao7,( Pinghuang( Liu8,(
Guozhong(Zhang9,*,(Yaokai(Chen10,*,(Kai(Deng2,11,*(&(Lilin(Ye1,*(

1

Institute(of(Immunology,(PLA,(Third(Military(Medical(University,(Chongqing(400038,(

China.(
2

Institute(of(Human(Virology,(Key(Laboratory(of(Tropical(Disease(Control(of(Ministry(of(

Education,( Zhongshan( School( of( Medicine,( Sun( Yat_sen( University,( Guangzhou(
510080,(China.(
3

Guangdong(Provincial(People's(Hospital,(Guangdong(Academy(of(Medical(Sciences,(

Guangzhou(510080,(China.(
4

State( Key( Laboratory( of( Veterinary( Biotechnology,( Harbin( Veterinary( Research(

Institute,( Chinese( Academy( of( Agricultural( Sciences,( Harbin,( Heilongjiang( 150001,(
China.(
5

College(of(Veterinary(Medicine,(Northeast(Agricultural(University,(Harbin(Heilongjiang,(

150030,(China.(
6

Cancer( Center,( The( General( Hospital( of( Western( Theater( Command,( Chengdu,(

Sichuan(610083,(China.(
7

Biomedical( Analysis( Center,( Third( Military( Medical( University,( Chongqing( 400038,(

China.(
8

Comparative( Immunology( Research( Center,( College( of( Veterinary( Medicine,( China(

Agricultural(University,(Beijing(100193,(China.(
9

Key( Laboratory( of( Animal( Epidemiology( of( the( Ministry( of( Agriculture,( College( of(

Veterinary(Medicine,(China(Agricultural(University,(Beijing(100193,(China.(
10

Chongqing(Public(Health(Medical(Center,(Chongqing(400038,(China.(

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

11

Guangzhou( Eighth( People’s( Hospital,( Guangzhou( Medical( University,( Guangzhou,(

510050,(China.(
12
*

These(authors(contributed(equally(to(this(work.(

Corresponding( authors:( Guozhong( Zhang( (zhanggz@cau.edu.cn),( Yaokai( Chen(

(yaokaichen@hotmail.com),( Kai( Deng( (dengkai6@mail.sysu.edu.cn)( and( Lilin( Ye(
(yelilinlcmv@tmmu.edu.cn).(
&

&

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Abstract&
COVID_19(patients(exhibit(differential(disease(severity(after(SARS_CoV_2(infection.(It(
is( currently( unknown( as( to( the( correlation( between( the( magnitude( of( neutralizing(
antibody((NAb)(responses(and(the(disease(severity(in(COVID_19(patients.(In(a(cohort(
of(59(recovered(patients(with(disease(severity(including(severe,(moderate,(mild(and(
asymptomatic,( we( observed( the( positive( correlation( between( serum( neutralizing(
capacity(and(disease(severity,(in(particular,(the(highest(NAb(capacity(in(sera(from(the(
patients(with(severe(disease,(while(a(lack(of(ability(of(asymptomatic(patients(to(mount(
competent(NAbs.(Furthermore,(the(compositions(of(NAb(subtypes(were(also(different(
between( recovered( patients( with( severe( symptoms( and( with( mild_to_moderate(
symptoms.( These( results( reveal( the( tremendous( heterogeneity( of( SARS_CoV_2_
specific( NAb( responses( and( their( correlations( to( disease( severity,( highlighting( the(
needs(of(future(vaccination(in(COVID_19(patients(recovered(from(asymptomatic(or(mild(
illness.( (
(

(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Introduction&
As(of(July(28,(2020,(the(pandemic(of(coronavirus(disease(2019((COVID_19),(caused(
by( severe( acute( respiratory( syndrome( coronavirus( 2( (SARS_CoV_2)( infection,( has(
claimed( 16,341,920( clinically( confirmed( cases( and( 650,805( deaths( worldwide1.( The(
infected(patients(show(heterogeneous(clinical(manifestations,(which(can(be(generally(
classified( into( four( groups,( including( severe,( moderate,( mild( and( asymptomatic,(
according(to(the(severity(of(symptoms2.(Despite(daily(increasing(confirmed(cases(and(
death,(currently(no(medical(agents(are(approved(to(prevent(SARS_CoV_2(infection(or(
treat(COVID_19(patients.(
(
A(growing(body(of(evidence(shows( that(recovered(COVID_19(patients(can(generate(
IgG_type(antibodies(specifically(binding(to(various(structure(proteins(of(SARS_CoV_2(
particles( shortly( after( the( onset( of( disease,( albeit( at( variable( levels3_6.(Among( these(
virus(specific(antibodies,(only(those(capable(of(blocking(SARS_CoV_2(spike((S)(protein(
mediated( viral( attachment( and/or( entry( of( host( cells,( called( neutralizing( antibodies(
(NAbs),(can(effectively(curtail(infection7.(The(convalescent(plasma(or(sera(containing(
NAbs( harvested( from( recovered( patients( have( shown( promising( results( in( treating(
COVID_19(patients(of(critical(illness(in(several(small_scale(clinic(trials8_11.(In(addition,(a(
variety( of( human( monoclonal( antibodies( (mAbs)( of( potent( SARS_CoV_2( neutralizing(
activities(has(been(cloned(from(memory(B(cells(from(recovered(COVID_19(patients12_
21

,(holding(great(potentials(for(prophylactic(or(therapeutic(use.(However,(little(is(known(

regarding(the(relationship(between(disease(severity(and(the(magnitude(of(SARS_CoV_
2_specific( NAbs( responses( in( patients( recovered( from( COVID_19.( Defining( the(
association(of(disease(severity(to(NAb(responses(will(facilitate(the(screening(of(COVID_
19( recovered( patients( as( therapeutic( plasma( donors( as( well( as( memory( B( cell(
providers(for(cloning(high_affinity(human(neutralizing(mAbs(to(prevent(or(treat(COVID_
19.( (
(
The( circulation( of( high_titer( NAbs( provides( the( immediate( protection( against(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

corresponding( viral( infections,( which( can( be( achieved( by( recovering( from( natural(
infection( or( by( inducing( from( vaccine( immunization.( Thus( far,( there( is( no( vaccine(
approved( for( COVID_19( prophylaxis,( albeit( several( types( of( COVID_19( vaccines,(
including( inactivated,( vector_based,( DNA( and( mRNA( vaccines22_25,( are( undergoing(
early(stages(of(clinical(trials.(Additionally,(the(NAb(titers(can(predict(the(possibility(of(
re_infection(in(patients(recovered(from(a(primary(viral(infection.(Currently,(there(are(few(
clues(regarding(whether(the(patients(recovered(from(COVID_19(can(be(protected(from(
re_infection(or(will(still(require(vaccination(in(the(future(when(effective(vaccines(become(
available.(
(
Results&
Antibody& responses& to& SARS0CoV02& in& COVID019& recovered& patients& with&
different&symptom&severity&
To(explore(the(potential(association(between(SARS_CoV_2(S(protein_specific(antibody(
responses(and(the(disease(severity(in(recovered(COVID_19(patients,(we(included(a(
cohort( of( 59( adult( patients,( 48( of( mild( (n=4),( moderate( (n=34)( and( severe( (n=10)(
symptoms( admitted( to( Guangzhou( Eighth( People’s( Hospital( and( 11( asymptomatic(
adult(patients(admitted(to(Chongqing(Public(Health(Center(Hospital.(The(median(age(
of( these( patients( was( 47( (33_62,( interquartile( range( (IQR))( years( oldm( 50.8%( of( the(
patients( were( femalem( Serum( samples( were( collected( at( the( day( of( discharge( after(
symptom(resolution(and(SARS_CoV_2(nucleotide(testing(negative(twice(by(RT_PCR.(
The(median(time(between(the(onset(of(symptom(to(sample(collection(was(20((12_30,(
IQR)(days.(The(asymptomatic(patients(were(identified(by(screening(those(with(close_
contact( history( to( COVID_19( patients( and( confirmed( by( SARS_CoV_2( RT_PCR.( The(
disease( severity( was( stratified( into( asymptomatic,( mild,( moderate( and( severe,(
according(to(the(national(diagnosis(and(treatment(guideline(of(COVID_19((7th(edition)(
in(China((Supplementary(Table(1).( (
(
The(SARS_CoV_2(spike(protein(consists(of(S1(and(S2(subunits.(The(receptor(binding(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

domain((RBD)(within(S1(subunit(is(essential(for(virus(attachment(to(host(cell(receptor,(
human(angiotensin_converting(enzyme(2((ACE2),(while(S2(is(critical(for(virus(entry(by(
mediating( viral( membrane( fusion( to( host( cell( membrane26_28.( Both( S1_RBD( and( S2(
represent(important(potential(targets(of(NAbs7.(We(first(compared(the(antibodies(that(
specifically(binding(to(S1,(RBD(and(S2(of(SARS_CoV_2(in(sera(of(COVID_19(recovered(
patients( with( different( illness( severity( by( IgG( ELISA.( Notably,( severe( and( moderate(
symptomatic( patients( mounted( the( most( and( second( robust( S1,( S1_RBD( and( S2(
specific( antibodies,( respectively,( while( mild( and( asymptomatic( patients( exhibited(
significantly(lower(abundances(of(S1_,(S1_RBD_(and(S2_specific(antibodies((Fig.1a_c),(
highlighting(the(disease(severity(as(a(key(determinant(factor(of(the(levels(of(antibodies(
specific(to(SARS_CoV_2(S(proteins.( (
(
Next,(we(assessed(the(abilities(of(antibodies(in(these(COVID_19(recovered(patients(to(
block(the(interaction(between(RBD(and(ACE2.(Similar(to(SARS_CoV_2(RBD(binding(
antibodies,( the( sera( from( recovered( patients( with( severe( symptoms( displayed( the(
highest( scores( of( blocking( RBD_ACE2( engagement,( followed( by( patients( with(
moderate(symptoms,(while(antibodies(from(mild(and(asymptomatic(patients(showed(
much(inferior(capacity(to(inhibit(RBD_ACE2(interaction((Fig.(2a,(b).( (
(
Neutralizing&antibody&responses&to&SARS0CoV02&in&COVID019&recovered&patients&
Subsequently,( we( conducted( SARS_CoV_2( S_protein( pseudotyped_lentiviral( based(
neutralization( assay( to( examine( the( neutralization( capacity( of( sera( from( COVID_19(
recovered(patients.(Such(assay(has(been(proven(to(be(free(of(biosafety(issue(but(as(
reliable(as(the(canonical(plaque(assay(with(authentic(SARS_CoV_217,19,21.(We(observed(
that(the(sera(neutralization(capacity(was(positively(correlated(to(disease(severity((Fig.(
2c).( Specifically,( 80%( of( patients( with( severe( symptoms( and( 47.1%( of( patients( with(
moderate( symptoms( generated( antibodies( capable( of( completely( neutralizing(
pseudovirus( infection,( while( only( 25%( of( serum( samples( from( patients( with( mild(
symptoms(were(able(to(block(pseudovirus(infectionm(strikingly,(sera(from(asymptomatic(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

patients(showed(no(activity(to(neutralize(pseudovirus(infection(in(this(assay((Fig.(2d).(
Next,( we( performed( neutralization( assay( with( the( authentic( SARS_CoV_2( to( explore(
the(neutralization(capacity(of(sera(from(COVID_19(recovered(patients.(In(accordance(
with( the( pseudotyped_lentiviral( based( neutralization( assay,( we( found( that( the( sera(
neutralization(capacity(of(severe(patients(was(the(highest(and(was(61.1_fold,(1319.1_
fold(and(2972.0_fold(higher(than(those(of(moderate,(mild(and(asymptomatic(patients,(
respectively((Fig.(2e,(f).(
(
Furthermore,(the(binding(abilities(of(S1,(RBD(and(S2(were(positively(correlated(to(each(
other( (Supplementary( Fig.( 1a_c)( and( also( positively( correlated( to( both( pseudovirus(
neutralizing( capacities( (Supplementary( Fig.( 1d_f)( and( authentic( SARS_CoV_2( virus(
neutralizing(capacities((Supplementary(Fig.(1g_i).(These(data(together(suggested(that(
the( disease( severity( determines( both( the( magnitude( and( neutralizing( capacity( of(
SARS_CoV_2_specific(antibodies(in(recovered(COVID_19(patients.(
(
Subtypes& of& neutralizing& antibodies& to& SARS0CoV02& S& proteins& in& COVID019&
recovered&patients&
Given(that(NAbs(can(potentially(target(both(S1(and(S2(to(block(viral(infection7,(we(set(
out(to(distinguish(S1(and(S2_specific(NAbs(in(COVID_19(patients(with(aforementioned(
pseudovirus( neutralization( assay.( To( this( end,( we( used( biotin_labeled( S1( or( S2(
recombinant( protein( to( deplete( corresponding( antibodies( in( sera( from( 25( COVID_19(
patients( that( were( confirmed( to( be( highly( neutralizing( in( Fig.( 2c( and( Fig.( 2e(
(Supplementary(Fig.(2a,(b).(After(depletion,(we(found(that(across(all(neutralizing(sera,(
40%(of(patients(generated(both(competent(S1_(and(S2_NAbs((i.e.,(post(either(S1_(or(
S2_specific( antibody( depletion,( sera( can( still( completely( neutralize( pseudovirusesm(
labeled(as(“S1/S2_NAbs”)m(while(40%(of(patients(only(generated(S1_competent(NAbs(
(“S1_NAbs( only”),( and( 4%( of( patients( only( generated( S2_specific( NAbs( (“S2_NAbs(
only”)m(interestingly,(16%(of(serum(samples(strictly(depended(on(the(collaboration(of(
S1_(and(S2_specific(NAbs(to(effectively(neutralize(pseudovirus(infection((i.e.,(either(S1_(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

or(S2_specific(antibody(depletion(in(the(serum(can(result(in(the(failure(of(neutralizationm(
labeled(as(“(S1+S2)_NAbs”)((Fig.(3a,(b).(Among(NAbs(in(severe(symptomatic(patients,(
the( majority( of( sera( (62.5%)( potently( neutralized( both( S1_mediated( receptor(
attachment( and( S2_mediated( membrane( fusion,( while( 37.5%( only( blocked( S1_
mediated(receptor(engagement((Fig.(3c).(For(mild(to(moderate(symptomatic(patients,(
NAb( features( were( more( diverse:( 41.2%( of( them( consisted( of( only( S1_neutralizing(
NAbs,( 29.4%( possessed( the( abilities( to( block( both( receptor( engagement( and(
membrane(fusion.(Notably,(23.5%(of(these(sera(required(the(combination(of(S1_(and(
S2_specific(NAbs(to(effectively(neutralize(pseudovirus(infection((Fig.(3c).(Collectively,(
our(data(revealed(the(highly(heterogeneous(nature(of(NAb(responses(against(SARS_
CoV_2( S( protein( and( such( diversity( seemed( to( be( closely( associated( with( disease(
severity.( The( immune( mechanisms( underlying( the( diversity( of( NAbs( responses( in(
COVID_19(patients(with(different(degree(of(symptoms(warrant(further(investigations.( ( ( (
(
Finally,(we(investigated(whether(NAbs(depleted(by(S1_recombinant(protein(are(actually(
targeting( RBD( for( their( neutralizing( capacity.( For( this( purpose,( we( depleted( RBD_
specific(antibodies(in(10(serum(samples(showing(S1_specific(neutralization(by(biotin_
conjugated(RBD(protein(mediated(pull_down((Supplementary(Fig.(2c).(Antibodies(post(
RBD_depletion(were(shown(to(lose(RBD_binding(ability,(but(still(keep(their(binding(to(
both(S1(and(S2(proteins,(suggesting(the(efficiency(and(specificity(of(RBD(Ab(depletion(
(Supplementary( Fig.( 2c_e).( Notably,( all( sera( with( S1_specific( neutralization( failed( to(
neutralize( pseudovirus( infection( after( RBD_specific( NAb( depletion( (Fig.( 3d,( e),(
demonstrating( the( strict( dependency( of( RBD_specific( NAbs( to( disengage( viral(
attachment(to(the(host(receptor.(These(data(provided(the(rationale(for(exclusively(using(
RBD(as(S1_immunogen(in(vaccine(design,(in(particular,(given(that(several(reports(have(
shown(the(enhanced(disease(after(whole(S1(immunization29,30.( ( (
&
Discussion&
The( COVID_19( patients( show( stratified( symptoms,( including( asymptomatic,( mild,(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

moderate( and( severe2.( Using( RBD_ACE2( blockade,( pseudovirus( neutralization( and(
authentic(virus(neutralization,(we(observed(that(disease(severity(positively(correlates(
to( NAb( responses.( The( patients( recovered( from( severe( illness( mounted( the( most(
robust( NAb( responses.( Strikingly,( asymptomatic( patients( fail( to( generate( competent(
NAbs.( The( mechanisms( underlying( disease( severity( associated( NAb( responses( are(
elusive.(One(possible(explanation(is(that(the(induction(of(SARS_CoV_2_specific(NAb(
responses(requires(the(strengthened(and(prolonged(B_cell(receptor((BCR)(stimulation.(
Indeed,( enhanced( BCR( rearrangement( was( observed( in( COVID_19( patients( with(
severe( disease( symptom31.( This( may( provide( important( insights( into( the( COVID_19(
vaccine(design,(in(which(the(vaccine(regimens(should(release(enough(SARS_CoV_2(
immunogens(in(an(extended(period.( (
(
Given( the( critical( role( of( NAbs( in( protecting( viral( infection( in( airways,( the( recovered(
asymptomatic(patients(may(suffer(from(SARS_CoV_2(re_infection.(In(this(circumstance,(
these(patients(need(to(be(vaccinated(whenever(the(effective(vaccines(are(available.(
Thus( far,( it( is( unknown( as( to( the( protective( immunity( that( prevents( asymptomatic(
patients(from(progressing(to(more(severe(disease.(Probably,(these(patients(can(mount(
robust(SARS_CoV_2_specific(CD8+(T(cell(responses,(which(may(confer(the(protection(
by(directly(clearing(virus_infected(target(cells.(However,(this(hypothesis(needs(to(be(
confirmed(in(future(investigations.( (
(
Our( results( also( demonstrated( the( tremendous( heterogeneous( NAb( responses( in(
patients( capable( of( inducing( high_titer( NAbs.( The( majority( (80.7%)( of( patients( can(
produce( S1_specfic( NAbs,( and( half( patients( are( able( to( generate( S2_specific( NAbs.(
However,(only(around(40%(of(patients(generated(both(S1_(and(S2_specific(competent(
NAbs.( Particularly,( approximate( 7%( patients( had( to( depend( on( the( collaboration(
between( S1_( and( S2_specific( antibodies( for( efficient( viral( neutralization.( The(
mechanisms( underlying( the( heterogeneous( NAb( responses( in( recovered( patients(
remains( unknown( and( warrant( further( studies.( Notably,( all( S1_specific( NAbs( were(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

strictly( RBD( dependent( and( deletion( of( RBD_specific( antibodies( led( to( the( failure( in(
neutralization(in(S1_specific(sera.(These(results(highlighted(the(importance(of(S1_RBD(
itself,(but(not(other(parts(of(S1(protein,(in(inducing(competent(NAbs.( (
(
In(conclusion,(we(have(demonstrated(the(positive(correlation(between(the(magnitude(
of(NAb(responses(and(disease(severity(in(patients(recovered(from(COVID_19.(We(have(
also( found( that( disease( severity( also( influences( the( neutralization( heterogeneity( of(
SARS_CoV2_specific(antibodies.(Our(results(highlight(the(needs(to(include(mild_illness(
and(asymptomatic(patients(for(future(vaccination,(and(also(suggest(the(collection(of(
plasma(from(COVID_19(recovered(patients(should(be(restricted(to(those(with(moderate(
to( severe( symptoms( for( passive( antibody( therapy.( Our( data( also( provide( important(
rationale( for( exclusively( using( SARS_CoV_2( RBD( as( S1_immunogen( in( COVID_19(
vaccine(regime.(
&
Materials&and&methods&
Human& samples.( The( 59( COVID_19( recovered( patients( enrolled( in( the( study( were(
provided(written(informed(consent(and(from(different(sources.(The(sera(of(the(severe,(
moderate(and(mild(patients(were(obtained(from(Guangzhou(Eighth(People’s(Hospital.(
The(sera(of(the(asymptomatic(patients(were(obtained(from(Chongqing(Public(Health(
Medical( Center.( Healthy( control( subjects( were( 4( adult( participants( in( the( study.( The(
study(received(IRB(approvals(at(Guangzhou(Eighth(People’s(Hospital((KE202001134)(
and(Chongqing(Public(Health(Medical(Center((2020_023_01_KY).&
(
ELISA.(As(previously(described15,(50(ng(of(SARS_CoV_2(S1(protein((Sino(Biological,(
40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,(40592_V08B)(or(SARS_
CoV_2(S2(protein((Sino(Biological,(40590_V08B)(in(100(μl(PBS(per(well(was(coated(on(
ELISA(plates((Costar,(42592)(overnight(at(4oC.(The(ELISA(plates(were(blocked(for(1(
hour( with( 100( μl( blocking( buffer( (5%( FBS( and( 0.1%( Tween( 20( in( PBS)( and( then(
incubated(with(diluted(patient(or(healthy(control(sera(in(100(μl(blocking(buffer(for(1(hour.(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

After( washing( with( PBST( buffer( (0.1%( Tween( 20( in( PBS),( the( ELISA( plates( were(
incubated( with( anti_human( IgG( HRP( antibody( (Bioss( Biotech,( 0297D)( for( 45( min,(
followed(by(PBST(washing(and(addition(of(TMB(buffer((Beyotime,(P0209).(The(ELISA(
plates( were( allowed( to( react( for( 5_10( min( and( stopped( by( 1( M( HCl( stop( buffer.(The(
optical(density((OD)(value(was(detected(at(450(nm.&
&
ELISA0based&RBD0ACE2&binding&inhibition&assay.&As(previously(described15,(200(
ng(of(ACE2(protein((Sino(Biological,(10108_H08H)(in(100(μl(PBS(per(well(was(coated(
on(ELISA(plates(overnight(at(4oC.(The(ELISA(plates(were(blocked(for(1(hour(with(100(
μl( blocking( buffer( (5%( FBS( and( 0.1%( Tween( 20( in( PBS)m( meanwhile,( 50( μl( 10_fold(
diluted(patient(or(healthy(control(sera(were(incubated(with(7.5(ng(SARS_CoV_2(RBD_
mouse(FC(protein((Sino(Biological,(40592_V05H)(in(50(μl(blocking(buffer(for(1(hour.(
Then,(the(incubated(sera/SARS_CoV_2(RBD_mouse(FC(protein(mixture(was(added(into(
the(ELISA(plates(and(allowed(to(develop(for(30(min,(followed(by(PBST(washing(and(
incubation(with(anti_mouse(FC(HRP(antibody((Thermo(Fisher(Scientific,(A16084)(for(
30(min.(Next,(the(ELISA(plates(were(washed(with(PBST(and(treated(with(TMB(buffer(
(Beyotime,(P0209).(After(5(min,(the(ELISA(reaction(was(stopped(by(1(M(HCl(stop(buffer(
and(determined(at(450(nm.(The(RBD_ACE2(binding(inhibition(score(was(calculated(as:(
100 ×((1(_((OD450(value(of(patient(sera(/(OD450(value(of(healthy(control(sera)).( &
&
Pseudovirus& neutralization& assay.( The( pseudovirus( neutralization( assay( was(
previously( described15,32.( Briefly,( HEK_293T( cells( were( transfected( with( pLenti_
luciferase,( psPAX2,( and( 2019_nCov( S( plasmids( by( using( TransIT_293( Transfection(
reagent( (Mirus,( MIR( 2700).(After( 12( hours,( the( culture( media( was( changed( to( fresh(
media.(And(at(64(hours(after(transfection,(the(culture(supernatants(containing(SARS_
CoV_2( typed( pseudovirus( were( harvested.( Next,( 200_fold( diluted( patient( or( healthy(
control(sera(were(mixed(with(SARS_CoV_2(typed(pseudovirus(for(1(hour(at(37oC.(Then,(
the( ACE2_expressing( HEK_293T( (ACE2/293T)( cells( were( incubated( with( the(
sera/pseudovirus(mixture(overnight(and(then(cultured(with(fresh(media.(At(40(hours(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

after(the(mixture(incubation,(the(luciferase(activity(of(SARS_CoV_2(typed(pseudovirus_
infected(ACE2/293T(cells(were(measured(by(a(luciferase(reporter(assay(kit((Promega,(
E1910).( &
&
SARS0CoV02& serum& neutralization& assay.& Patient( sera( were( diluted( in( DMEM( (40(
fold_dilution)( and( mixed( with( an( equal( volume( of( 80_100( PFU( SARS_CoV_2(
(EPI_ISL_444969)(for(1(h(at(37°C.(Serum_virus(mixture(were(then(added(to(the(Vero(
E6(cell(monolayers(in(48_well(plates(and(incubated(at(37°C(in(5%(CO2(for(1(h.(After(
removing(the(inocula,(plates(were(overlaid(with(culture(medium(and(cultured(at(37°C(
for(48(h.(Subsequently,(viral(RNA(from(the(cultural(supernatants(was(extracted(and(the(
viral(RNA(copies(were(determined(by(quantitative(PCR(according(to(the(viral(detection(
kit’s(protocol((DAAN(Gene(Co.,(Ltd.(of(Sun(Yat_Sen(University).(All(experiments(related(
to( authentic( viruses( were( performed( in( the( certified( BSL_3( facility( of( Sun( Yat_sen(
University.(The(SARS_CoV_2(viral(RNA(fold(reduction(=(2(CT(value(of(sample(_(CT(value(of(mock).&
&
Depletion& of& SARS0CoV02& S& protein0specific& antibodies.( Firstly,( SARS_CoV_2( S1(
protein((Sino(Biological,(40591_V08H)(or(SARS_CoV_2(RBD(protein((Sino(Biological,(
40592_V08B)(or(SARS_CoV_2(S2(protein(was(conjugated(with(biotin(by(following(the(
manufacture’s( protocol( (Thermo( Fisher( Scientific,( A39257).( Then,( biotin_conjugated(
proteins(were(incubated(with(BeaverBeads(Mag(Streptavidin(Matrix((Beaver,(22305)(
at(4oC(for(1.5(hours.(After(washing(with(PBS,(the(SARS_CoV_2(S(protein(coupled(beads(
were( next( incubated( with( diluted( patient( sera( at( 4oC( for( 1.5( hours.( Then,( the(
supernatants(were(harvested(and(quality(controlled(by(ELISA(assays(for(SARS_CoV_
2(S(proteins.( &
&
Statistics.(The(SARS_CoV_2(antibody(titers(or(virus(neutralizing(function(of(the(sera(
belonging(to(patients(with(different(severity(were(compared(with(the(one_way(ANOVA(
test( (Tukey’s( multiple( comparisons( test).( The( cutoff( value( in( each( pseudovirus(
neutralizing(function(assay(was(determined(by(the(ROC(curve(analysis(and(was(of(the(

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

highest(likelihood(ratio.(Correlations(between(different(SARS_CoV_2(antibody(titers(or(
between(SARS_CoV_2(antibody(titers(and(pseudovirus(titers(or(between(SARS_CoV_2(
antibody(titers(and(SARS_CoV_2(virus(titers(were(analyzed(using(Pearson’s(correlation(
coefficient.( P( values( less( than( 0.05( were( defied( as( statistically( significant.( Prism( 6(
software(was(used(for(statistical(analysis.&
&
Data&availability&statements&
The( data( sets( in( the( study( are( available( from( the( corresponding( authors( upon(
reasonable(request.(
&
Acknowledgements&
This(work(was(supported(by(grants(from(the(National(Science(and(Technology(Major(
Project((No. 2017ZX10202102_006_002(to(L.Y.),(the(National(Natural(Science(Fund(for(
Distinguished( Young( Scholars( (No.( 31825011( to( L.Y.)( and( the( Chongqing( Special(
Research( Project( for( Novel( Coronavirus( Pneumonia( Prevention( and( Control( (No.(
cstc2020jscx_2(to(L.Y.m(No.(cstc2020jscx_fyzx0074(to(Y.C.m(cstc2020jscx_fyzx0135(to(
Y.C.).( (
&
Conflicts&of&interests&
The(authors(declare(no(competing(interests.(
(
Contributions&
X.C.,(Z.P.,(S.Y.,(F.Y.,(J.Z.,(Y.Y.,(R.L.,(B.L.,(X.Y.,(L.G.,(Z.L.,(Y.L.,(Q.H.,(L.X.,(J.T.,(L.H.(
and(J.Z.(performed(the(experiments.(L.Y.(designed(the(study,(analyzed(the(data(and(
wrote( the( paper( with( X.C.,( X.Z.,( P.L.,( Y.W.( and( K.D.m( and( G.Z.,( Y.C.,( K.D.( and( L.Y.(
supervised(the(study.(
(
&

&

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

References&
(

H9

)

H

4Z ZYLaT
K

OT PL P 4 G:5 (0 1 T L TZY CP Z (0' )')'

N8ZZRLY

4Z ZYLaT
CP Z

4SL LN P T TN ZQ LYO :X Z LY

5T PL P )'(0 4 G:5 (0

ZQ .) (

PO OZT1(' (' /&

ZY P

L

,

H

7 P LW

PO OZT1(' (' /&
P

Z D2CD 4ZG ) TY L TPY

Ld Z OP PN D2CD 4ZG ) P ZNZYaP TZY TY
(,0( ')' '0( , )')'

LWTeTYR LY TMZOd P

ZY P

Z D2CD 4ZG ) TY L 4 G:5 (0

XPOCcTa )')'

PNZaP PO L TPY NZSZ LYO SPT TX WTNL TZY
-

P LW 5P PN TZY ZQ D2CD 4ZG ) D PNTQTN 9 XZ LW LYO 4PWW WL :XX YT d

T
TY

4 G:5 (0

4ZYaLWP NPY

OZT1(' ('(-&U TXX YT )')' ' ')
.

9 LYR 2 E P LW 2
NZ ZYLaT

T

Z PN TZY LYO L

WL XL

Od XPOCcTa )')'

(0

ZY EPcL

)')'

bT S 4ZYaLWP NPY AWL XL

XPOCcTa )')'

P LW 6QQPN TaPYP
L TPY

HT S 4 G:5 (0 HT S

2 2 OZT1(' (''(&ULXL )')' ./

DLWLeL 6 P LW E PL XPY ZQ 4 G:5 (0 AL TPY

5 LY

ZNTL TZY ZQ

PL XPY ZQ PaP P 4 G:5 (01 2

DSPY 4 P LW E PL XPY ZQ , 4 T TNLWWd :WW AL TPY

TY 9Z
((

NZ PWL P ZQ

D E 9 P LW 4ZYaLWP NPY

4ZYaLWP NPY AWL XL
('

)')'

ZY P bT S PaP T d ZQ OT PL P XPOCcTa )')'

XL NSPO NZY ZW
0

:XX YT d

:YOTaTO LW

d PXL TN PaTPb ZQ LY TMZOd XPOTL PO TXX YT d Z

P 1 LY TMZOd VTYP TN

LY TMZOd P
/

bT S 4 G:5

(,0( ')' '/0. ( )')'

2XLYL 7 P LW 2 P ZWZRTNLW L
S XLY

M PLV TY 4STYL1 D XXL d ZQ L

4L P 7 ZX SP 4STYP P 4PY P QZ 5T PL P 4ZY ZW LYO

ZYR B I P LW 2Y TMZOd P

L

ZY 7 ZX SP

2 2 OZT1(' (''(&ULXL )')' )- / )')'

A PaPY TZY

(0

P

A ZN

ZQ NZYaLWP NPY

LW

2NLO

DNT

WL XL SP L d TY PaP P 4 G:5

F

D

2

((.

0 0' 0 0-

OZT1(' ('. & YL )'' (-/((. )')'
()

3L X 2 P LW 2Y TMZOd NZNV LTW Z D2CD 4ZG )
X L TZYLW

P NL P

PPY

bT S

TYOTaTO LW

TVP

Z PTY

LY TMZOTP

PaPY

L TO

DNTPYNP

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

OZT1(' (()-& NTPYNP LMO'/ ( )')'
(

P LW AZ PY YP

3 Z bP A

LWTeTYR LY TMZOTP Q ZX 4 G:5 (0 L TPY

ZQ a WYP LMTWT d DNTPYNP OZT1(' (()-& NTPYNP LMN,0')

OPQTYP X W T WP L RP
)')'
(

4LZ J P LW AZ PY YP
STRS S Z RS

LWTeTYR LY TMZOTP LRLTY

TYRWP NPWW P

D2CD 4ZG ) TOPY TQTPO Md

PYNTYR ZQ NZYaLWP NPY

L TPY

3 NPWW

4PWW

OZT1(' ('(-&U NPWW )')' ', '), )')'
(,

4SPY I P LW 9 XLY XZYZNWZYLW LY TMZOTP MWZNV SP MTYOTYR ZQ D2CD 4ZG
)

TVP

Z PTY Z LYRTZ PY TY NZYaP TYR PYedXP ) PNP Z 4PWW

(. - . - 0 OZT1(' (' /&

(-

ZW :XX YZW

( ) ')' ' )- . )')'

P LW D OTP TY S XLYTePO XTNP LYO NZYaLWP NPY S XLY dTPWO L

9LY PY

D2CD 4ZG ) LY TMZOd NZNV LTW DNTPYNP OZT1(' (()-& NTPYNP LMO'/). )')'
3 P LW 9 XLY YP

(.

L
(/

P OZT1(' (' /&

LWTeTYR LY TMZOTP PWTNT PO Md D2CD 4ZG ) TYQPN TZY

(,/- ')' ) /' e )')'

E 7 P LW : ZWL TZY ZQ Z PY D2CD 4ZG ) YP

CZRP

Z PN TZY

Q ZX

OT PL P

TY

L

XLWW

LYTXLW

LWTeTYR LY TMZOTP LYO

DNTPYNP

XZOPW

OZT1(' (()-& NTPYNP LMN.,)' )')'
(0

DST C P LW 2 S XLY YP
D2CD 4ZG )

)'

L

P OZT1(' (' /&

HPN 2 K P LW 3 ZLO YP
XZYZNWZYLW LY TMZOTP

)(

LWTeTYR LY TMZOd L RP

(,/- ')' ) /( d )')'

LWTeL TZY ZQ D2CD PWL PO aT

DNTPYNP OZT1(' (()-& NTPYNP LMN. )

P LW 9 XLY :R8 YP

HLY

SP PNP Z MTYOTYR T P ZQ

P

Md S XLY

)')'

LWTeTYR XZYZNWZYLW LY TMZOTP MWZNV D2CD 4ZG

) TYQPN TZY MTZCcTa )')'
))

8LZ B P LW CL TO OPaPWZ XPY ZQ LY TYLN TaL PO aLNNTYP NLYOTOL P QZ
D2CD 4ZG ) DNTPYNP OZT1(' (()-& NTPYNP LMN(0 ) )')'

)

J

P LW 5 2 aLNNTYP

Z PN TZY LRLTY

DNTPYNP OZT1(' (()-& NTPYNP LMN-)/
)

KS

7 4 P LW DLQP d

LOPYZaT

D2CD 4ZG ) TY SP

XLNL

P

)')'

ZWP LMTWT d LYO TXX YZRPYTNT d ZQ L PNZXMTYLY

d P , aPN Z PO 4 G:5 (0 aLNNTYP1 L OZ P P NLWL TZY Z PY WLMPW

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

),

YZY LYOZXT PO

QT

-. - )' ()'/

)')'

2XLYL 7

TY S XLY

LYNP

TLW

OZT1(' ('(-&D'( '

LXXP 7 D2CD 4ZG ) GLNNTYP 1 D L

:XX YT d ,)

CP Z

,/ ,/0 OZT1(' ('(-&U TXX YT )')' ' ''. )')'
)-

5 P LW 4 dZ 6

HL

N

P ZQ SP )'(0 Y4ZG

NZYQZ XL TZY DNTPYNP -. ()-' ()).

JLY C P LW D

N

T NSOZP QP

L

Z PTY
)0

P LW A P Q

C

XLN Z SLRP P

TZY

OZT1(' (()-& NTPYNP LMM),'. )')'

(

/ OZT1(' (()-& NTPYNP LMM).-) )')'

TZY

N

P ZQ L S XLY NZ ZYLaT

P , ( ((/ ()( OZT1(' (' /&YL

P LW 2Y T

T

PQ

LW ML T QZ SP PNZRYT TZY ZQ D2CD 4ZG ) Md Q WW WPYR S

S XLY 246) DNTPYNP -. (
)/

TVP TY SP

TVP :R8 NL

ZY P

P

TVP

P(.)'' )'(-

PaP P LN P W YR TYU d Md

VPbTYR

4: :Y TRS

O TYR LN P D2CD 4ZG TYQPN TZY

OZT1(' ((.)&UNT TY TRS () (,/ )'(0
'

P LW ESP

5

SP L P TN

TVP

Z PTY ZQ D2CD 4ZG L L RP QZ aLNNTYP LYO

L

OPaPWZ XPY

CPa

TN ZMTZW

.

))- ) -

OZT1(' (' /&Y XTN Z)'0' )''0
(

DNS W SPT

4 P LW

CP P ZT P

Q ZX 4 G:5 (0 AL TPY

Pc 8PYP L TZY DP

PYNTYR ZQ E LYO 3 4PWW CPNP Z

DSZbPO DTRYL

P

2

DPaP T d ZQ 5T PL P :XX YT d OZT1(' ('(-&U TXX YT )')' '- ')
)

IT d LY

J

ETYR 4SPY

TLcTYR 9

P TYR 9

ITLZMZ PT APT T 5LY

BT TY

KTNS Y ITLYR KSTcTL

RWdNZ Z PTY

5ZT1(' )()' &

TWT CPY

)')'

T 8 Z C Tc LY 8 Z

ITYR 4SPY

TPdZYR 4SPY

TLYbPT HLYR KSLZS T BTLY 4SL LN P TeL TZY ZQ

RWdNZ Z PTY ZQ )'(0 Y4ZG ZY aT
TVP

T

ZNTL PO bT S

ZQ

PY d LYO T
D2CD 4ZG

) ) '(-&a( )')'

TXX YP N Z

L

P

TVP

PLN TaT d bT S

4ZXX YTNL TZY

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 1

ns

1.5
1.0
0.5

ns

****
*

1.5

ns

**** ns

ns

1.0
0.5

pt
om
H
at
ea
ic
lth
y
co
nt
ro
l

M
ild

m
sy
A

A

sy

m

pt
om
H
at
ea
ic
lth
y
co
nt
ro
l

er
od

M
ild

e
at

re
ve
M

m
sy
A

**

0.0

Se

er
od
M

pt
om
H
at
ea
ic
lth
y
co
nt
ro
l

at

re
ve

M
ild

0.0

e

0.0

2.0

e

0.5

**** ns
ns

**

at

1.0

*

****

er

ns

**

od

**** ns

2.0

re

*

1.5

ns

ve

****

M

***

S2 binding ELISA

Se

*

Se

OD Value (450 nm)

2.0

c

RBD binding ELISA

OD Value (450 nm)

b

S1 binding ELISA

OD Value (450 nm)

a

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure' 1.' Antibody' responses' to' SARS5CoV52' in' COVID519' recovered'
patients'with'different'symptom'severity.!
a5c,!ELISA!binding!assays!of!1004fold!diluted!COVID419!patient!sera!to!ELISA!
plates!coating!of!SARS4CoV42!S1!(a),!RBD!(b)!and!S2!(c)!proteins.!The!dashed!
lines!in!a4c!represent!the!average!values!of!healthy!control!groups.!*P!<!0.05,!
**P!<!0.01,!***P!<!0.001!and!****P!<!0.0001.!Not!significant,!ns.!Error!bars!in!a4
c!indicate!SEM.!
!

!

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 2
a

RBD-ACE2 binding inhibition ELISA

*

*

**
Inhibition score

RBD-ACE2 binding inhibition score high (>50) and low (<50)

ns
ns

ns

100

b

All cases

Severe

Moderate

Mild

Asymptomatic

40.7% | 59.3%

70.0% | 30.0%

38.2% | 61.8%

25.0% | 75.0%

27.3% | 72.7%

75
50
25

ic
at
om

A

sy

m

M

pt

od

Se

er

ve

at

re

e

M
ild

0

c
luciferase value (Log2)

Pseudovirus neutralization assay
20.0

*

*

17.5

****

Pseudovirus neutralization positive (<cutoff value) and negative (>cutoff value)

ns

**

ns

d

ns

ns

All cases

Severe

Moderate

Mild

36.2% | 63.8%

80.0% | 20.0%

47.1% | 52.9%

25.0% | 75.0%

Asymptomatic

15.0
12.5
10.0
7.5
0% | 100.0%

A

sy

m

pt
om
H
ea
at
lth
ic
y
N
co
eg
nt
at
ro
iv
l
e
co
nt
ro
l

M
ild

e
at
er

M

od

Se

ve

re

5.0

e
106

**

**

105

****
**

f

!"#$%&'()*+%,+-.++)%/)$/&(-+$%-."%*0"123%/)%!/*45+

ns

**

!"#"$"

!"#"$"

%&'"$()"

%*+'

,-./0)&/()*1

2

3454

464754

87985:

%&'"$()"

3454

2

8453

;<53

104

%*+'

464754

8453

2

856

103

,-./0)&/()*1

87985:

;<53

856

2

102
101

A

sy

m

M

pt

om

at

ic

M
ild

od

er

ve

at

re

e

100

Se

Viral RNA fold reduction

SARS-CoV-2 neutralization assay

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure' 2.' Neutralizing' antibody' responses' to' SARS5CoV52' in' COVID519'
recovered'patients.!
a,! Scores! showing! the! COVID419! patient! serum4mediated! inhibition! of! the!
SARS4CoV42! RBD! protein! binding! to! ACE2! protein! by! ELISA.! b,! Pie! charts!
showing!the!proportions!of!patients!with!high!(>!50,!green)!or!low!(<!50,!red)!
RBD4ACE2! binding! inhibition! score! in! each! indicated! situations.! c,! Patient!
serum4mediated! blocking! of! luciferase4encoding! SARS4CoV42! typed!
pseudovirus!into!ACE2/293T!cells.!The!dashed!line!indicates!the!cutoff!value!
(7.121)! determined! by! the! ROC! curve! analysis.! d,! Pie! charts! showing! the!
proportions!of!patients!with!pseudovirus!neutralization4positive!(<!7.121,!green)!
or! 4negative! (>! 7.121,! red)! in! each! indicated! situations.! e,! Patient! serum4
mediated!blocking!of!SARS4CoV42!virus!into!Vero!E6!cells.!f,!A!table!showing!
the!fold!change!of!SARS4CoV42!viral!RNA!fold!reduction!between!indicated!two!
groups!in!(e).!*P!<!0.05,!**P!<!0.01!and!****P!<!0.0001.!Not!significant,!ns.!Error!
bars!in!a,!c,!e!indicate!SEM.!
!

!

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure 3
a

No depletion
S1-Abs depletion
S2-Abs depletion

Log2 luciferase value

15.0

b

Patients of pseudovirus
neutralization-positive (n=25)

12.5

40.0%, S1-NAbs only
10.0

4.0%, S2-NAbs only
16.0%, (S1+S2)-NAbs

7.5

40.0%, S1/S2-NAbs

Severe

54
H
C
N
C

53

52

46

35

31

29

22
26

17

16

14

13

9
10

1

7

51

45

44

36

34

19

4
18

5.0
Moderate and mild

c

e
Severe (n=8)

Patients of S1-nAbs only
(n=10)

Moderate and mild (n=17)

37.5%, S1-NAbs

41.2%, S1-NAbs

100.0%:

0%, S2-NAbs

5.9%, S2-NAbs

RBD-NAbs-dependent

0%, (S1+S2)-NAbs

23.5%, (S1+S2)-NAbs

0.0%:

62.5%, S1/S2-NAbs

29.4%, S1/S2-NAbs

RBD-NAbs-independent

d
No depletion
RBD-Abs depletion

12.5
10.0
7.5

Severe

Moderate and mild

C
N

C
H

54

52

29

26

22

9

1

51

44

5.0

34

Log2 luciferase value

15.0

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Figure'3.'Subtypes'of'neutralizing'antibodies'to'SARS5CoV52'S'proteins'
in'COVID519'recovered'patients.'
a,! Blocking! of! luciferase4encoding! SARS4CoV42! typed! pseudovirus! into!
ACE2/293T!cells!by!patient!sera!(no!depletion)!or!S1!antibodies4depleted!sera!
(S14Abs! depletion)! or! S2! antibodies4depleted! sera! (S24Abs! depletion).! The!
dashed! line! indicates! the! cutoff! value! (6.749)! determined! by! the! ROC! curve!
analysis.!HC,!healthy!control.!NC,!negative!control.!b5c,!Pie!charts!showing!the!
proportions! of! patients! with! different! neutralizing! antibody! (NAb)! subtype!
responses!in!the!total!25!patients!(b),!8!severe!patients!(c,!left!panel)!and!17!
moderate! and! mild! patients! (c,! right! panel)! of! pseudovirus! neutralization4
positive.! d,! Blocking! of! luciferase4encoding! SARS4CoV42! typed! pseudovirus!
into! ACE2/293T! cells! by! “S14NAbs! only”! patient! sera! with! RBD! antibodies!
depletion! (RBD4Abs! depletion)! or! without! RBD! antibodies! depletion! (no!
depletion).!The!dashed!line!indicates!the!cutoff!value!(6.034)!determined!by!the!
ROC! curve! analysis.! HC,! healthy! control.! NC,! negative! control.! e,! Pie! chart!
showing!the!proportions!of!“S14NAbs!only”!patients!with!RBD4NAbs4dependent!
or!4independent!antibody!response.!Error!bars!in!a,!d!indicate!SEM.!

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint

Supplementary
Figure
1 by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was
not certified
All rights reserved. No reuse allowed without permission.

a

b

r=0.8861
P < 0.0001

2.0

Severe, **
Moderate, ****
Mild, ns
Asymptomatic, *

1.5
1.0

RBD binding (OD450)

S2 binding (OD450)

2.0

0.5
0.0
0.0

0.5

1.0

1.5

r=0.9565
P < 0.0001

1.5
1.0
0.5
0.0
0.0

2.0

Severe, **
Moderate, ****
Mild, *
Asymptomatic, **

0.5

1.0

1.5

2.0

S1 binding (OD450 value)

S1 binding (OD450 value)

c

d
r=0.8514
P < 0.0001

2.0

Severe, *
Moderate, ****
Mild, ns
Asymptomatic, ns

1.5
1.0

S1 binding (OD450)

RBD binding (OD450)

2.0

0.5
0.0
0.0

0.5

1.0

1.5

r=-0.6557
P < 0.0001

1.5
1.0
0.5
0.0
5.0

2.0

Severe, ns
Moderate, **
Mild, ns
Asymptomatic, **

7.5

10.0

12.5

15.0

Log2 luciferase value

S2 binding (OD450 value)

e

f
r=-0.7096
P < 0.0001

2.0

Severe, *
Moderate, ***
Mild, ns
Asymptomatic, *

1.5
1.0

S2 binding (OD450)

RBD binding (OD450)

2.0

0.5
0.0
5.0

7.5

10.0

12.5

r=-0.6093
P < 0.0001

1.5
1.0
0.5
0.0
5.0

15.0

Severe, **
Moderate, **
Mild, ns
Asymptomatic, ns

7.5

Log2 luciferase value

10.0

12.5

15.0

Log2 luciferase value

h
S1 binding (OD450)

2.0

r=0.5216
P < 0.0001

Severe, *
Moderate, *
Mild, ns
Asymptomatic, ns

1.5
1.0
0.5

-1

0

1

2

3

4

5

6

S2 binding (OD450)

Severe, *
Moderate, *
Mild, *
Asymptomatic, ns

1.5
1.0
0.5

-1

0

1

2

3

4

5

6

SARS-CoV-2 viral RNA reduction (Log10)

Severe, *
Moderate, *
Mild, ns
Asymptomatic, ns

1.0
0.5

0

1

2

3

4

5

6

SARS-CoV-2 viral RNA reduction (Log10)

i
r=0.5546
P < 0.0001

r=0.5386
P < 0.0001

1.5

-1

SARS-CoV-2 viral RNA reduction (Log10)

2.0

2.0
RBD binding (OD450)

g

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Supplementary, Figure, 1., Correlation, analyses, of, SARS8CoV82, antibody,
titers,and,neutralizing,functions,in,COVID819,recovered,patients.!
a8c,!Correlations!between!SARS2CoV22!S1!antibody!titer!and!SARS2CoV22!S2!
antibody! titer! (a),! SARS2CoV22! S1! antibody! titer! and! SARS2CoV22! RBD!
antibody! titer! (b)! and! SARS2CoV22! S2! antibody! titer! and! SARS2CoV22! RBD!
antibody! titer! (c)! in! the! 59! COVID219! recovered! patients.! d8f,! Correlations!
between! SARS2CoV22! S1! antibody! titer! and! SARS2CoV22! pseudovirus!
neutralizing! function! (d),! SARS2CoV22! RBD! antibody! titer! and! SARS2CoV22!
pseudovirus! neutralizing! function! (e)! and! SARS2CoV22! S2! antibody! titer! and!
SARS2CoV22! pseudovirus! neutralizing! function! (f)! in! the! 59! COVID219!
recovered! patients.! g8i,! Correlations! between! SARS2CoV22! S1! antibody! titer!
and! SARS2CoV22! virus! neutralizing! function! (g),! SARS2CoV22! RBD! antibody!
titer! and! SARS2CoV22! virus! neutralizing! function! (h)! and! SARS2CoV22! S2!
antibody!titer!and!SARS2CoV22!virus!neutralizing!function!(i)!in!the!59!COVID2
19! recovered! patients.!The! P! value! and! r! value! at! the! top! left! of! each! panel!
assess! the! correlation! between! the! indicated! two! parameters! in! the! total! 59!
patients.!The!asterisks!adjacent!to!severity!at!the!top!right!of!each!panel!assess!
the!correlation!between!the!indicated!two!parameters!in!patients!of!indicated!
severity.!*P!<!0.05,!**P!<!0.01,!***P!<!0.001!and!****P!<!0.0001.!Not!significant,!
ns.! !
,

,

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint

Supplementary
Figure
2 by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was
not certified
All rights reserved. No reuse allowed without permission.
No depletion
S1-Abs depletion
S2-Abs depletion

2.5
2.0
1.5
1.0
0.5

Severe

53
54
H
C

52

35
46

29
31

26

22

16
17

14

13

9
10

7

1

51

45

36
44

19
34

0.0

4
18

S1 binding assay (OD450)

a

Moderate and mild

No depletion
S1-Abs depletion
S2-Abs depletion

1.5

1.0

0.5

Severe

54
H
C

53

52

35
46

31

29

26

22

17

16

14

13

10

9

7

1

51

45

36
44

19
34

0.0

4
18

S2 binding assay (OD450)

b

Moderate and mild

c
RBD binding (OD450)

1.0

No depletion
RBD-Abs depletion

0.8
0.6
0.4
0.2

Severe

C
H

54

52

29

26

22

9

1

51

44

34

0.0

Moderate and mild

d
S1 binding (OD450)

1.0

No depletion
RBD-Abs depletion

0.8
0.6
0.4
0.2

Severe

C
H

54

52

29

26

22

9

1

51

44

34

0.0

Moderate and mild

e
No depletion
RBD-Abs depletion

0.8
0.6
0.4
0.2

Severe

Moderate and mild

C
H

54

52

29

26

22

9

1

51

44

0.0

34

S2 binding (OD450)

1.0

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
All rights reserved. No reuse allowed without permission.

Supplementary,Figure,2.,Depletion,efficiencies,of,SARS8CoV82,S1,,S2,and,
RBD,antibodies,in,patient,sera.,
a,, b,, ELISA! binding! assays! of! 15002fold! diluted! COVID219! patient! sera! (no!
depletion)!or!S1!antibodies2depleted!sera!(S12Abs!depletion)!or!S2!antibodies2
depleted!sera!(S22Abs!depletion)!to!ELISA!plates!coating!of!SARS2CoV22!S1!
(a)!and!S2!(b)!proteins.!HC,!healthy!control.!c8e,!ELISA!binding!assays!of!15002
fold!diluted!COVID219!patient!sera!(no!depletion)!or!RBD!antibodies2depleted!
sera!(RBD2Abs!depletion)!to!ELISA!plates!coating!of!SARS2CoV22!RBD!(c),!S1!
(d)!and!S2!(e)!proteins.!HC,!healthy!control.!

medRxiv preprint doi: https://doi.org/10.1101/2020.07.29.20164285; this version posted July 30, 2020. The copyright holder for this preprint

Supplementary
Table
1 by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
(which was
not certified
All rights reserved. No reuse allowed without permission.
Supplementary Table 1. Characteristics of patients from the study
!""#$%&'()

*+,+-+#$%&./)

012+-34+#$%&56)

07"2#$%&6)

!89:;41:347<#$%&..)

!"#$%%&'()

'!#$*+&",)

!'#$%!&'()

(-#$(,&%()

!(#$(!&!.)

#####D+:3"+

%,#$*,/+0)

!#$!,/,0)

-+#$*(/.0)

!#$-,,/,0)

!#$%'/!0)

#####03"+

(.#$!./(0)

'#$',/,0)

-'#$!"/-0)

,#$,0)

"#$'%/'0)

E%8+4#1F#89:;41:#41
83:;"+#<1""+<471%>2398
$:+273%?#@AB)

(,#$-(&%,)

-"#$-!&(-)

(,#$-,&(.)

(!#$(,&(")

(%#$(,&%()

(,(,1-1('
$(,(,1-1(!#23#(,(,1-1(+)

(,(,1-1("
$(,(,1-1(*#23#(,(,1(1%)

(,(,1%1((
$(,(,1%1--#23#(,(,1%1(%)

(,(,1!1.
$(,(,1%1("#23#(,(,1!1-!)

!=+>9+3-8#$:+273%?#@AB)
C+%2+-

G18;743"#32:78871%#234+
(,(,1-1%,
$:+27H:?#@AB)
$(,(,1-1(*#23#(,(,1%1-%)

1. Continuous variables were shown as the median (interquartile range, IQR).
2. All the 59 COVID-19 patients were tested positive qPCR for SARS-CoV-2 virus RNA upon hospital admission. Patients were diagnosed as severe when
meeting any one of the following conditions: 1) anhelation (RR ≥ 30/min), 2) SpO2 ≤ 93%, 3) PaO2/FiO2 ≤ 300 mmHg and 4) imageological diagnosis of
signigicant progress (> 50%) in 24-48 hours. The moderate patients were diagnosed with respiratory symptoms, fever and imageological evidence of pneumonia.
The mild patients were diagnosed with mild clinical symptoms and no imageological evidence of pneumonia. The asymptomatic patients were those without
clinical symptoms.

